8-K: Elutia Announces Strong EluPro Demand in Pilot Launch, Setting Stage for Full Commercial Roll-Out

Elutia Inc. reports strong initial market uptake for EluPro, driving BioEnvelope sales up 18% and same-center sales up 65% following its commercialization.

Summary

• Elutia Inc. announced its fourth quarter and full year 2024 financial results, highlighting strong demand for EluPro following its pilot launch.
• EluPro, an antibiotic-eluting biomatrix, has been adopted across major cardiac implantable electronic device (CIED) brands and is gaining traction in neurostimulator applications.
• The company closed 2024 with 67 approved EluPro accounts and approximately 100 actively ordering accounts.
• Agreements with major national group purchasing organizations (GPOs) like Premier, Inc. and Southern Strategic Sourcing Partners (S3P) are supporting sales growth.
• For the full year 2024, BioEnvelope product sales increased by 5% to $9.9 million, while SimpliDerm sales increased by 12% to $11.6 million.
• Cardiovascular product sales decreased by 42% to $2.9 million due to a change in the sales model with LeMaitre Vascular.
• Overall net sales decreased by 1.5% to $24.4 million.
• The GAAP gross margin was 43.9%, and the adjusted gross margin was 57.9%.
• The net loss from continuing operations was $54.1 million, and the adjusted EBITDA loss was $12.9 million.
• Elutia raised approximately $15 million in a registered direct offering that closed on February 4, 2025, and the cash balance as of December 31, 2024, was $13.2 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strong initial uptake of EluPro and growth in certain product lines, but is tempered by overall revenue decline and significant net losses.

Positives

• Strong initial market uptake for EluPro, indicating a positive market reception.
• Increased BioEnvelope sales, driven by EluPro, demonstrating growth in this product line.
• Growth in SimpliDerm sales, contributing to overall revenue.
• Improved adjusted EBITDA loss, suggesting better cost management.
• Successful capital raise of $15 million, strengthening the company's financial position.
• Sales growth is further supported by agreements with major national group purchasing organizations (GPOs), including Premier, Inc. and Southern Strategic Sourcing Partners (S3P).

Negatives

• Overall net sales decreased by 1.5% for the full year.
• Cardiovascular product sales decreased significantly due to a change in the sales model.
• The company reported a net loss from continuing operations of $54.1 million.
• Total operating expenses increased to $46.4 million.
• Net sales of SimpliDerm decreased 23% to $2.3 million for the three-month period ended December 31, 2024, compared to $3.0 million.

Risks

• The company's ability to successfully commercialize and market EluPro is crucial for future growth.
• Dependence on commercial partners and independent sales agents to generate a substantial portion of net sales poses a risk.
• Competition from other companies with more established products and greater resources could impact market share.
• Pricing pressure from cost-containment efforts of customers and payors could affect sales and profitability.
• The company's ability to obtain regulatory approval for new products and product candidates is essential for long-term success.
• The company's ability to continue as a going concern is dependent on achieving or sustaining profitability.

Future Outlook

The company anticipates continued growth driven by the full commercial roll-out of EluPro and expansion through VACs and GPO relationships.

Management Comments

• Dr. Randy Mills, CEO of Elutia, stated that EluPro has quickly gained traction with physicians and hospital groups.
• Dr. Randy Mills believes EluPro is the most complete solution for device protection in the $600 million market.

Industry Context

Elutia is operating in the drug-eluting biomatrix technology space, targeting the $600 million market for device protection. The successful pilot launch of EluPro positions the company to compete with existing solutions for cardiac implantable electronic devices (CIEDs) and neurostimulators.

Comparison to Industry Standards

• It's difficult to directly compare Elutia's performance to industry standards without knowing the specific growth rates and profitability metrics of its direct competitors in the biomatrix and drug-eluting device market.
• Companies like Medtronic, Abbott, and Boston Scientific also operate in the broader medical device market, but their financial results are influenced by a wider range of products and services.
• Elutia's 5% growth in BioEnvelope sales and 12% growth in SimpliDerm sales should be compared to the average growth rates of similar companies in the advanced wound care and implantable device markets to assess its relative performance.
• The adjusted EBITDA loss of $12.9 million should be benchmarked against the profitability of comparable companies to determine if Elutia is on track to achieve profitability.

Stakeholder Impact

• Shareholders: The financial results and future outlook will impact shareholder value.
• Employees: The company's performance and growth prospects will affect job security and opportunities.
• Customers: The availability and adoption of EluPro will impact patient outcomes and treatment options.
• Suppliers: The company's sales and production volumes will influence supplier relationships and demand.
• Creditors: The company's financial stability and ability to repay debt will be of concern to creditors.

Next Steps

• Full commercial roll-out of EluPro.
• Continued engagement with Value Analysis Committees (VACs) and Group Purchasing Organizations (GPOs).
• Active discussions with multiple parties exploring partnering opportunities.

Key Dates